{"gene":"CYBC1","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":2017,"finding":"Eros (mouse ortholog of CYBC1) is required for expression of NADPH oxidase components gp91phox and p22phox in phagocytes; Eros-deficient mice rapidly succumb to infection, and Eros also contributes to neutrophil extracellular trap (NET) formation","method":"Loss-of-function mouse genetics, immunoblotting for gp91phox/p22phox, infection assays, NET assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — clean KO mouse with defined cellular and in vivo phenotypes, replicated across multiple readouts","pmids":["28351984"],"is_preprint":false},{"year":2018,"finding":"CYBC1/EROS deficiency in human cells reduces abundance of the gp91phox–p22phox heterodimer of the phagocyte NADPH oxidase, establishing EROS as a regulator of this complex; loss-of-function mutations cause chronic granulomatous disease","method":"Patient mutation analysis, immunoblotting for gp91phox and p22phox in EROS-deficient human phagocytes, oxidative burst assays","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 — human patient cells with defined biochemical and functional phenotype, corroborated by independent Icelandic cohort study","pmids":["30312704","30361506"],"is_preprint":false},{"year":2019,"finding":"EROS is localized to the endoplasmic reticulum and acts as a chaperone for P2X7, transiently associating with P2X7 to promote formation of a stable homotrimeric P2X7 complex; EROS-null cells lose P2X7-mediated phosphatidylserine exposure, phospholipid scrambling, dye uptake, Ca2+ transport, and IL-1β secretion","method":"Genome-wide CRISPR screen, subcellular fractionation/ER localization, co-immunoprecipitation of EROS–P2X7, functional assays (PtdSer exposure, YO-PRO-1 uptake, Ca2+ flux, IL-1β ELISA) in Eros-null cell lines and primary macrophages","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — CRISPR screen + reciprocal Co-IP + multiple orthogonal functional readouts in primary and cell-line models","pmids":["31862710"],"is_preprint":false},{"year":2022,"finding":"EROS acts at the earliest stages of gp91phox maturation: it directly binds the immature 58 kDa gp91phox, prevents its degradation, enables glycosylation via the oligosaccharyltransferase machinery, and allows incorporation of heme prosthetic groups essential for catalysis; EROS also directly interacts with purine receptors P2X7 and P2X1, and P2X7 is nearly absent in EROS-deficient mouse and human primary cells; combined loss of ROS and P2X7 signalling confers resistance to influenza infection in mice","method":"Co-immunoprecipitation of EROS with immature gp91phox, glycosylation and heme-incorporation assays, proteomic interactome (mass spectrometry), P2X7/P2X1 direct binding assays, Eros-KO mouse model with influenza infection, inflammasome and T cell functional assays","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal biochemical assays plus in vivo mouse model; elucidates full chaperone mechanism","pmids":["36421765"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structure of the EROS–NOX2–p22phox heterotrimeric complex at 3.56 Å resolution shows EROS and p22phox on opposite sides of NOX2 with no direct contact; EROS binds NOX2 via two antiparallel transmembrane α-helices and β-strands forming hydrogen bonds with the NOX2 cytoplasmic domain; EROS binding induces a 79° bend of TM2 and 48° rotation of TM6 in NOX2, increasing heme–heme distance and shifting FAD binding site, placing NOX2 in a protected/inactive state; PMA stimulation dissociates EROS from NOX2 with concurrent increase in FAD binding and superoxide production","method":"Cryo-EM structure determination, site-specific mutagenesis, PMA-induced dissociation assay in COS-7 transfected cells, superoxide production assay, HL-60 differentiated neutrophil-like cell surface localization studies","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — high-resolution cryo-EM structure with functional activation assays in cellular models","pmids":["38805284"],"is_preprint":false},{"year":2024,"finding":"EROS plays a role in ROS-dependent signal transduction in vascular endothelial cells: EROS knockdown/knockout decreases NOX2 protein abundance and RAC1 levels, attenuates agonist-induced H2O2 and Ca2+ signalling, disrupts cytoskeleton organization, decreases cell migration, promotes cellular senescence, and blocks eNOS phosphorylation and nitric oxide generation; proteomic analysis shows EROS and RAC1 knockdown produce largely overlapping effects on endothelial oxidoreductase and eNOS pathways","method":"siRNA knockdown and CRISPR/Cas9 KO in HUVEC, immunoblotting for NOX2 and RAC1, ROS assays, Ca2+ imaging, cell migration assays, senescence assays, eNOS phosphorylation by western blot, quantitative proteomics","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods in a single laboratory, novel cellular context not independently replicated","pmids":["38805973"],"is_preprint":false},{"year":2011,"finding":"Human C17orf62 (CYBC1) protein contains a signal peptide and transmembrane domain, partially co-localizes with the Golgi apparatus, and its overexpression induces cell death accompanied by cleavage of PARP","method":"RT-PCR cloning, confocal microscopy for subcellular localization, flow cytometry for cell phenotype, western blot for cleaved PARP","journal":"Beijing da xue xue bao. Yi xue ban","confidence":"Low","confidence_rationale":"Tier 3 — single lab, single set of methods; early characterization not independently replicated and partially superseded by ER localization data","pmids":["21503106"],"is_preprint":false},{"year":2024,"finding":"CYBC1 positively regulates NOXA1 (a NOX1-complex subunit) expression in glioblastoma cells, thereby enhancing ROS production and activating ERK/AKT/NF-κB pathways; CYBC1 CRISPR KO reduces cell viability, migration, invasion, ROS levels, and NF-κB phosphorylation, and downregulates epithelial-mesenchymal transition genes","method":"CRISPR/Cas9 KO in GBM cell lines, immunoblotting for NOXA1 and NF-κB phosphorylation, ROS assays, cell migration/invasion assays, cell viability assays","journal":"Cancer research and treatment","confidence":"Low","confidence_rationale":"Tier 3 — single lab, single paper; mechanistic pathway placement is preliminary with no independent replication","pmids":["39727012"],"is_preprint":false}],"current_model":"CYBC1/EROS is an endoplasmic reticulum-resident transmembrane chaperone that directly binds immature gp91phox (NOX2) to prevent its degradation, facilitate its glycosylation and heme incorporation, and stabilize the gp91phox–p22phox heterodimer of the phagocyte NADPH oxidase; a cryo-EM structure reveals that EROS holds NOX2 in a protected, FAD-shifted conformation that is released upon activation, and EROS additionally acts as a selective chaperone for the purinergic receptors P2X7 and P2X1, making it a critical regulator of both ROS-mediated killing and purinergic innate immune signalling."},"narrative":{"teleology":[{"year":2017,"claim":"Establishing that EROS is required for phagocyte NADPH oxidase expression and host defense resolved the long-standing question of whether additional factors beyond known NOX2 subunits were needed for oxidase biogenesis.","evidence":"Eros-knockout mice showed loss of gp91phox/p22phox protein, failed oxidative burst, lethal susceptibility to infection, and impaired NET formation","pmids":["28351984"],"confidence":"High","gaps":["Mechanism by which EROS controls gp91phox/p22phox abundance was not defined","Whether EROS acts as a transcriptional regulator or post-translational chaperone was unknown","Human relevance not yet demonstrated"]},{"year":2018,"claim":"Demonstrating that human CYBC1 loss-of-function mutations cause chronic granulomatous disease established EROS as a bona fide disease gene and confirmed conservation of the oxidase-regulatory function from mouse to human.","evidence":"Patient mutation analysis, immunoblotting for gp91phox/p22phox, and oxidative burst assays in EROS-deficient human phagocytes; corroborated by independent Icelandic cohort","pmids":["30312704","30361506"],"confidence":"High","gaps":["Direct physical interaction between EROS and NOX2 subunits not yet shown","Subcellular site of action not established"]},{"year":2019,"claim":"Identifying EROS as an ER-resident chaperone for P2X7 expanded its functional scope beyond NOX2 and revealed it promotes homotrimeric assembly of a client receptor through transient association.","evidence":"Genome-wide CRISPR screen, ER localization by subcellular fractionation, reciprocal co-immunoprecipitation of EROS–P2X7, and multiple functional readouts (PtdSer exposure, dye uptake, Ca²⁺ flux, IL-1β secretion) in knockout cell lines and primary macrophages","pmids":["31862710"],"confidence":"High","gaps":["Structural basis of EROS–P2X7 interaction unknown","Whether EROS chaperones additional client proteins beyond NOX2 and P2X7 was unresolved"]},{"year":2022,"claim":"Defining the precise step at which EROS acts — binding immature 58 kDa gp91phox to enable glycosylation and heme loading — established its role as an early biogenesis chaperone rather than a late stabilizer, and extended its client repertoire to include P2X1.","evidence":"Co-immunoprecipitation with immature gp91phox, glycosylation/heme-incorporation assays, proteomic interactome by mass spectrometry, P2X1 binding assays, and Eros-KO mouse influenza infection model","pmids":["36421765"],"confidence":"High","gaps":["Atomic-level mechanism of EROS-mediated NOX2 stabilization unknown","How EROS is released upon NOX2 maturation was unclear"]},{"year":2024,"claim":"A cryo-EM structure of the EROS–NOX2–p22phox heterotrimer revealed the structural mechanism: EROS binds NOX2 via transmembrane helices and induces conformational distortions that increase heme–heme distance and shift the FAD site, locking NOX2 in a protected state that is released upon activation.","evidence":"3.56 Å cryo-EM, site-directed mutagenesis, PMA-induced dissociation assays in transfected COS-7 cells, superoxide production assays, and HL-60 differentiated neutrophil-like cell surface localization","pmids":["38805284"],"confidence":"High","gaps":["Structure of EROS bound to P2X7 or P2X1 clients not determined","In vivo dynamics of EROS dissociation during neutrophil activation not characterized","Whether EROS re-engages NOX2 after activation is unknown"]},{"year":2024,"claim":"Extending EROS function to vascular endothelial cells showed it regulates NOX2 and RAC1 abundance, ROS-dependent calcium signaling, eNOS activation, and cell migration, broadening its physiological relevance beyond phagocytes.","evidence":"siRNA knockdown and CRISPR KO in HUVECs with ROS assays, Ca²⁺ imaging, senescence assays, eNOS phosphorylation, and quantitative proteomics","pmids":["38805973"],"confidence":"Medium","gaps":["Endothelial findings from a single laboratory, not independently replicated","Whether EROS directly chaperones RAC1 or affects it indirectly through NOX2 is unresolved","In vivo vascular phenotype of EROS deficiency not tested"]},{"year":null,"claim":"Key unresolved questions include the structural basis of EROS interaction with P2X7/P2X1 clients, the full client repertoire of EROS as an ER chaperone, the mechanism governing EROS recycling or degradation after client release, and the in vivo relevance of EROS in non-immune cell types such as endothelium.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural data for EROS–P2X7 or EROS–P2X1 complexes","Comprehensive client profiling via unbiased interactomics not yet performed across tissue types","Post-dissociation fate of EROS protein is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[2,3,4]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[2,3,4]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,2,3]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,3,4]}],"complexes":["NADPH oxidase (NOX2–p22phox–EROS)"],"partners":["CYBB","CYBA","P2RX7","P2RX1"],"other_free_text":[]},"mechanistic_narrative":"CYBC1 (also called EROS) is an endoplasmic reticulum-resident transmembrane chaperone essential for the biogenesis and stabilization of the phagocyte NADPH oxidase (NOX2) and purinergic receptor complexes, thereby governing reactive oxygen species production and innate immune signaling. EROS directly binds immature gp91phox (NOX2) in the ER, preventing its degradation and facilitating glycosylation and heme incorporation required for assembly of the catalytically competent gp91phox–p22phox heterodimer; a 3.56 Å cryo-EM structure shows EROS holds NOX2 in a protected, FAD-shifted conformation via two antiparallel transmembrane helices, and activation-dependent stimulation dissociates EROS to permit superoxide production [PMID:28351984, PMID:36421765, PMID:38805284]. EROS additionally serves as a selective chaperone for purinergic receptors P2X7 and P2X1, transiently associating with P2X7 to promote stable homotrimer formation and enabling downstream inflammasome activation and IL-1β secretion [PMID:31862710, PMID:36421765]. Loss-of-function mutations in CYBC1 cause chronic granulomatous disease in humans [PMID:30312704, PMID:30361506]."},"prefetch_data":{"uniprot":{"accession":"Q9BQA9","full_name":"Cytochrome b-245 chaperone 1","aliases":["Essential for reactive oxygen species protein","Eros"],"length_aa":187,"mass_kda":20.8,"function":"Functions as a chaperone necessary for a stable expression of the CYBA and CYBB subunits of the cytochrome b-245 heterodimer (PubMed:30361506). Controls the phagocyte respiratory burst and is essential for innate immunity (By similarity)","subcellular_location":"Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/Q9BQA9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CYBC1","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CCDC47","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/CYBC1","total_profiled":1310},"omim":[{"mim_id":"618935","title":"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 5; CGD5","url":"https://www.omim.org/entry/618935"},{"mim_id":"618334","title":"CYTOCHROME b(-254) CHAPERONE 1; CYBC1","url":"https://www.omim.org/entry/618334"},{"mim_id":"608508","title":"CYTOCHROME b(-245), ALPHA SUBUNIT; CYBA","url":"https://www.omim.org/entry/608508"},{"mim_id":"306400","title":"GRANULOMATOUS DISEASE, CHRONIC, X-LINKED; CGDX","url":"https://www.omim.org/entry/306400"},{"mim_id":"300481","title":"CYTOCHROME b(-245), BETA SUBUNIT; CYBB","url":"https://www.omim.org/entry/300481"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Plasma membrane","reliability":"Uncertain"},{"location":"Cell Junctions","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CYBC1"},"hgnc":{"alias_symbol":["MGC4368","FLJ90469","Eros"],"prev_symbol":["C17orf62"]},"alphafold":{"accession":"Q9BQA9","domains":[{"cath_id":"2.30.29","chopping":"3-20_64-163","consensus_level":"medium","plddt":87.5752,"start":3,"end":163}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BQA9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BQA9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BQA9-F1-predicted_aligned_error_v6.png","plddt_mean":83.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CYBC1","jax_strain_url":"https://www.jax.org/strain/search?query=CYBC1"},"sequence":{"accession":"Q9BQA9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BQA9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BQA9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BQA9"}},"corpus_meta":[{"pmid":"30361506","id":"PMC_30361506","title":"A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30361506","citation_count":79,"is_preprint":false},{"pmid":"30312704","id":"PMC_30312704","title":"EROS/CYBC1 mutations: Decreased NADPH oxidase function and chronic granulomatous disease.","date":"2018","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30312704","citation_count":63,"is_preprint":false},{"pmid":"28351984","id":"PMC_28351984","title":"Eros is a novel transmembrane protein that controls the phagocyte respiratory burst and is essential for innate immunity.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28351984","citation_count":51,"is_preprint":false},{"pmid":"31386577","id":"PMC_31386577","title":"Basal Hormones and Biochemical Markers as Predictors of Overtraining Syndrome in Male Athletes: The EROS-BASAL Study.","date":"2019","source":"Journal of athletic training","url":"https://pubmed.ncbi.nlm.nih.gov/31386577","citation_count":46,"is_preprint":false},{"pmid":"19331021","id":"PMC_19331021","title":"Event-related oscillations (EROs) and event-related potentials (ERPs) comparison in facial expression recognition.","date":"2007","source":"Journal of neuropsychology","url":"https://pubmed.ncbi.nlm.nih.gov/19331021","citation_count":45,"is_preprint":false},{"pmid":"29313445","id":"PMC_29313445","title":"Body composition, metabolism, sleep, psychological and eating patterns of overtraining syndrome: Results of the EROS study (EROS-PROFILE).","date":"2018","source":"Journal of sports sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29313445","citation_count":26,"is_preprint":false},{"pmid":"31548891","id":"PMC_31548891","title":"Novel causes and consequences of overtraining syndrome: the EROS-DISRUPTORS study.","date":"2019","source":"BMC sports science, medicine & rehabilitation","url":"https://pubmed.ncbi.nlm.nih.gov/31548891","citation_count":23,"is_preprint":false},{"pmid":"31862710","id":"PMC_31862710","title":"Functional Expression of the P2X7 ATP Receptor Requires Eros.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/31862710","citation_count":15,"is_preprint":false},{"pmid":"21474805","id":"PMC_21474805","title":"Developing a tool to assess quality of stroke care across European populations: the EROS Quality Assessment Tool.","date":"2011","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/21474805","citation_count":12,"is_preprint":false},{"pmid":"37055004","id":"PMC_37055004","title":"Characterization of AR-CGD female patient with a novel homozygous deletion in CYBC1 gene presenting with unusual clinical phenotype.","date":"2023","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/37055004","citation_count":11,"is_preprint":false},{"pmid":"37673227","id":"PMC_37673227","title":"A novel mutation in EROS (CYBC1) causes chronic granulomatous disease.","date":"2023","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/37673227","citation_count":10,"is_preprint":false},{"pmid":"36421765","id":"PMC_36421765","title":"EROS is a selective chaperone regulating the phagocyte NADPH oxidase and purinergic signalling.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/36421765","citation_count":10,"is_preprint":false},{"pmid":"16246124","id":"PMC_16246124","title":"Defining the protein-protein interactions of the mammalian endoplasmic reticulum oxidoreductases (EROs).","date":"2005","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/16246124","citation_count":7,"is_preprint":false},{"pmid":"31125060","id":"PMC_31125060","title":"EROS-DOCK: protein-protein docking using exhaustive branch-and-bound rotational search.","date":"2019","source":"Bioinformatics (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31125060","citation_count":7,"is_preprint":false},{"pmid":"21220109","id":"PMC_21220109","title":"EROS: Better than SAXS!","date":"2011","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/21220109","citation_count":7,"is_preprint":false},{"pmid":"38805973","id":"PMC_38805973","title":"An essential role for EROS in redox-dependent endothelial signal transduction.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/38805973","citation_count":6,"is_preprint":false},{"pmid":"33406484","id":"PMC_33406484","title":"Novel Markers of Recovery From Overtraining Syndrome: The EROS-LONGITUDINAL Study.","date":"2021","source":"International journal of sports physiology and performance","url":"https://pubmed.ncbi.nlm.nih.gov/33406484","citation_count":5,"is_preprint":false},{"pmid":"34280579","id":"PMC_34280579","title":"HSCT in two brothers with CGD arising from mutations in CYBC1 corrects the defect in neutrophil function.","date":"2021","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/34280579","citation_count":4,"is_preprint":false},{"pmid":"32670198","id":"PMC_32670198","title":"Eating, Sleep, and Social Patterns as Independent Predictors of Clinical, Metabolic, and Biochemical Behaviors Among Elite Male Athletes: The EROS-PREDICTORS Study.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32670198","citation_count":4,"is_preprint":false},{"pmid":"38805284","id":"PMC_38805284","title":"Structural basis for EROS binding to human phagocyte NADPH oxidase NOX2.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/38805284","citation_count":3,"is_preprint":false},{"pmid":"32506478","id":"PMC_32506478","title":"Using restraints in EROS-DOCK improves model quality in pairwise and multicomponent protein docking.","date":"2020","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/32506478","citation_count":3,"is_preprint":false},{"pmid":"38896305","id":"PMC_38896305","title":"First Report on Chronic Granulomatous Disease from Nepal and a Review of CYBC1 Deficiency.","date":"2024","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38896305","citation_count":2,"is_preprint":false},{"pmid":"29024415","id":"PMC_29024415","title":"EroS Enzyme from Aliivibrio fischeri Plays Cupid to Choanoflagellates.","date":"2017","source":"Chembiochem : a European journal of chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/29024415","citation_count":1,"is_preprint":false},{"pmid":"39727012","id":"PMC_39727012","title":"CYBC1 Drives Glioblastoma Progression via Reactive Oxygen Species and NF-κB Pathways.","date":"2024","source":"Cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/39727012","citation_count":0,"is_preprint":false},{"pmid":"21503106","id":"PMC_21503106","title":"[Study on the mechanism of C17orf62 induced cell death].","date":"2011","source":"Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21503106","citation_count":0,"is_preprint":false},{"pmid":"18763473","id":"PMC_18763473","title":"The transformative potential of realigning Agape and Eros in the continued development of nursing's role.","date":"2008","source":"Research and theory for nursing practice","url":"https://pubmed.ncbi.nlm.nih.gov/18763473","citation_count":0,"is_preprint":false},{"pmid":"17094373","id":"PMC_17094373","title":"Eros and psychotic despair.","date":"2006","source":"The Psychoanalytic quarterly","url":"https://pubmed.ncbi.nlm.nih.gov/17094373","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.06.19.660615","title":"EVODEX: A Mechanistic Framework for Extracting, Structuring, and Predicting Enzymatic Reactivity","date":"2025-06-25","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.19.660615","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":12485,"output_tokens":2397,"usd":0.036705},"stage2":{"model":"claude-opus-4-6","input_tokens":5731,"output_tokens":2195,"usd":0.125295},"total_usd":0.162,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2017,\n      \"finding\": \"Eros (mouse ortholog of CYBC1) is required for expression of NADPH oxidase components gp91phox and p22phox in phagocytes; Eros-deficient mice rapidly succumb to infection, and Eros also contributes to neutrophil extracellular trap (NET) formation\",\n      \"method\": \"Loss-of-function mouse genetics, immunoblotting for gp91phox/p22phox, infection assays, NET assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO mouse with defined cellular and in vivo phenotypes, replicated across multiple readouts\",\n      \"pmids\": [\"28351984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CYBC1/EROS deficiency in human cells reduces abundance of the gp91phox–p22phox heterodimer of the phagocyte NADPH oxidase, establishing EROS as a regulator of this complex; loss-of-function mutations cause chronic granulomatous disease\",\n      \"method\": \"Patient mutation analysis, immunoblotting for gp91phox and p22phox in EROS-deficient human phagocytes, oxidative burst assays\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human patient cells with defined biochemical and functional phenotype, corroborated by independent Icelandic cohort study\",\n      \"pmids\": [\"30312704\", \"30361506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"EROS is localized to the endoplasmic reticulum and acts as a chaperone for P2X7, transiently associating with P2X7 to promote formation of a stable homotrimeric P2X7 complex; EROS-null cells lose P2X7-mediated phosphatidylserine exposure, phospholipid scrambling, dye uptake, Ca2+ transport, and IL-1β secretion\",\n      \"method\": \"Genome-wide CRISPR screen, subcellular fractionation/ER localization, co-immunoprecipitation of EROS–P2X7, functional assays (PtdSer exposure, YO-PRO-1 uptake, Ca2+ flux, IL-1β ELISA) in Eros-null cell lines and primary macrophages\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR screen + reciprocal Co-IP + multiple orthogonal functional readouts in primary and cell-line models\",\n      \"pmids\": [\"31862710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EROS acts at the earliest stages of gp91phox maturation: it directly binds the immature 58 kDa gp91phox, prevents its degradation, enables glycosylation via the oligosaccharyltransferase machinery, and allows incorporation of heme prosthetic groups essential for catalysis; EROS also directly interacts with purine receptors P2X7 and P2X1, and P2X7 is nearly absent in EROS-deficient mouse and human primary cells; combined loss of ROS and P2X7 signalling confers resistance to influenza infection in mice\",\n      \"method\": \"Co-immunoprecipitation of EROS with immature gp91phox, glycosylation and heme-incorporation assays, proteomic interactome (mass spectrometry), P2X7/P2X1 direct binding assays, Eros-KO mouse model with influenza infection, inflammasome and T cell functional assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal biochemical assays plus in vivo mouse model; elucidates full chaperone mechanism\",\n      \"pmids\": [\"36421765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structure of the EROS–NOX2–p22phox heterotrimeric complex at 3.56 Å resolution shows EROS and p22phox on opposite sides of NOX2 with no direct contact; EROS binds NOX2 via two antiparallel transmembrane α-helices and β-strands forming hydrogen bonds with the NOX2 cytoplasmic domain; EROS binding induces a 79° bend of TM2 and 48° rotation of TM6 in NOX2, increasing heme–heme distance and shifting FAD binding site, placing NOX2 in a protected/inactive state; PMA stimulation dissociates EROS from NOX2 with concurrent increase in FAD binding and superoxide production\",\n      \"method\": \"Cryo-EM structure determination, site-specific mutagenesis, PMA-induced dissociation assay in COS-7 transfected cells, superoxide production assay, HL-60 differentiated neutrophil-like cell surface localization studies\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution cryo-EM structure with functional activation assays in cellular models\",\n      \"pmids\": [\"38805284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"EROS plays a role in ROS-dependent signal transduction in vascular endothelial cells: EROS knockdown/knockout decreases NOX2 protein abundance and RAC1 levels, attenuates agonist-induced H2O2 and Ca2+ signalling, disrupts cytoskeleton organization, decreases cell migration, promotes cellular senescence, and blocks eNOS phosphorylation and nitric oxide generation; proteomic analysis shows EROS and RAC1 knockdown produce largely overlapping effects on endothelial oxidoreductase and eNOS pathways\",\n      \"method\": \"siRNA knockdown and CRISPR/Cas9 KO in HUVEC, immunoblotting for NOX2 and RAC1, ROS assays, Ca2+ imaging, cell migration assays, senescence assays, eNOS phosphorylation by western blot, quantitative proteomics\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in a single laboratory, novel cellular context not independently replicated\",\n      \"pmids\": [\"38805973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Human C17orf62 (CYBC1) protein contains a signal peptide and transmembrane domain, partially co-localizes with the Golgi apparatus, and its overexpression induces cell death accompanied by cleavage of PARP\",\n      \"method\": \"RT-PCR cloning, confocal microscopy for subcellular localization, flow cytometry for cell phenotype, western blot for cleaved PARP\",\n      \"journal\": \"Beijing da xue xue bao. Yi xue ban\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, single set of methods; early characterization not independently replicated and partially superseded by ER localization data\",\n      \"pmids\": [\"21503106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CYBC1 positively regulates NOXA1 (a NOX1-complex subunit) expression in glioblastoma cells, thereby enhancing ROS production and activating ERK/AKT/NF-κB pathways; CYBC1 CRISPR KO reduces cell viability, migration, invasion, ROS levels, and NF-κB phosphorylation, and downregulates epithelial-mesenchymal transition genes\",\n      \"method\": \"CRISPR/Cas9 KO in GBM cell lines, immunoblotting for NOXA1 and NF-κB phosphorylation, ROS assays, cell migration/invasion assays, cell viability assays\",\n      \"journal\": \"Cancer research and treatment\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, single paper; mechanistic pathway placement is preliminary with no independent replication\",\n      \"pmids\": [\"39727012\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CYBC1/EROS is an endoplasmic reticulum-resident transmembrane chaperone that directly binds immature gp91phox (NOX2) to prevent its degradation, facilitate its glycosylation and heme incorporation, and stabilize the gp91phox–p22phox heterodimer of the phagocyte NADPH oxidase; a cryo-EM structure reveals that EROS holds NOX2 in a protected, FAD-shifted conformation that is released upon activation, and EROS additionally acts as a selective chaperone for the purinergic receptors P2X7 and P2X1, making it a critical regulator of both ROS-mediated killing and purinergic innate immune signalling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CYBC1 (also called EROS) is an endoplasmic reticulum-resident transmembrane chaperone essential for the biogenesis and stabilization of the phagocyte NADPH oxidase (NOX2) and purinergic receptor complexes, thereby governing reactive oxygen species production and innate immune signaling. EROS directly binds immature gp91phox (NOX2) in the ER, preventing its degradation and facilitating glycosylation and heme incorporation required for assembly of the catalytically competent gp91phox–p22phox heterodimer; a 3.56 Å cryo-EM structure shows EROS holds NOX2 in a protected, FAD-shifted conformation via two antiparallel transmembrane helices, and activation-dependent stimulation dissociates EROS to permit superoxide production [PMID:28351984, PMID:36421765, PMID:38805284]. EROS additionally serves as a selective chaperone for purinergic receptors P2X7 and P2X1, transiently associating with P2X7 to promote stable homotrimer formation and enabling downstream inflammasome activation and IL-1β secretion [PMID:31862710, PMID:36421765]. Loss-of-function mutations in CYBC1 cause chronic granulomatous disease in humans [PMID:30312704, PMID:30361506].\",\n  \"teleology\": [\n    {\n      \"year\": 2017,\n      \"claim\": \"Establishing that EROS is required for phagocyte NADPH oxidase expression and host defense resolved the long-standing question of whether additional factors beyond known NOX2 subunits were needed for oxidase biogenesis.\",\n      \"evidence\": \"Eros-knockout mice showed loss of gp91phox/p22phox protein, failed oxidative burst, lethal susceptibility to infection, and impaired NET formation\",\n      \"pmids\": [\"28351984\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism by which EROS controls gp91phox/p22phox abundance was not defined\",\n        \"Whether EROS acts as a transcriptional regulator or post-translational chaperone was unknown\",\n        \"Human relevance not yet demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating that human CYBC1 loss-of-function mutations cause chronic granulomatous disease established EROS as a bona fide disease gene and confirmed conservation of the oxidase-regulatory function from mouse to human.\",\n      \"evidence\": \"Patient mutation analysis, immunoblotting for gp91phox/p22phox, and oxidative burst assays in EROS-deficient human phagocytes; corroborated by independent Icelandic cohort\",\n      \"pmids\": [\"30312704\", \"30361506\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct physical interaction between EROS and NOX2 subunits not yet shown\",\n        \"Subcellular site of action not established\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identifying EROS as an ER-resident chaperone for P2X7 expanded its functional scope beyond NOX2 and revealed it promotes homotrimeric assembly of a client receptor through transient association.\",\n      \"evidence\": \"Genome-wide CRISPR screen, ER localization by subcellular fractionation, reciprocal co-immunoprecipitation of EROS–P2X7, and multiple functional readouts (PtdSer exposure, dye uptake, Ca²⁺ flux, IL-1β secretion) in knockout cell lines and primary macrophages\",\n      \"pmids\": [\"31862710\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of EROS–P2X7 interaction unknown\",\n        \"Whether EROS chaperones additional client proteins beyond NOX2 and P2X7 was unresolved\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defining the precise step at which EROS acts — binding immature 58 kDa gp91phox to enable glycosylation and heme loading — established its role as an early biogenesis chaperone rather than a late stabilizer, and extended its client repertoire to include P2X1.\",\n      \"evidence\": \"Co-immunoprecipitation with immature gp91phox, glycosylation/heme-incorporation assays, proteomic interactome by mass spectrometry, P2X1 binding assays, and Eros-KO mouse influenza infection model\",\n      \"pmids\": [\"36421765\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Atomic-level mechanism of EROS-mediated NOX2 stabilization unknown\",\n        \"How EROS is released upon NOX2 maturation was unclear\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A cryo-EM structure of the EROS–NOX2–p22phox heterotrimer revealed the structural mechanism: EROS binds NOX2 via transmembrane helices and induces conformational distortions that increase heme–heme distance and shift the FAD site, locking NOX2 in a protected state that is released upon activation.\",\n      \"evidence\": \"3.56 Å cryo-EM, site-directed mutagenesis, PMA-induced dissociation assays in transfected COS-7 cells, superoxide production assays, and HL-60 differentiated neutrophil-like cell surface localization\",\n      \"pmids\": [\"38805284\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structure of EROS bound to P2X7 or P2X1 clients not determined\",\n        \"In vivo dynamics of EROS dissociation during neutrophil activation not characterized\",\n        \"Whether EROS re-engages NOX2 after activation is unknown\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extending EROS function to vascular endothelial cells showed it regulates NOX2 and RAC1 abundance, ROS-dependent calcium signaling, eNOS activation, and cell migration, broadening its physiological relevance beyond phagocytes.\",\n      \"evidence\": \"siRNA knockdown and CRISPR KO in HUVECs with ROS assays, Ca²⁺ imaging, senescence assays, eNOS phosphorylation, and quantitative proteomics\",\n      \"pmids\": [\"38805973\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Endothelial findings from a single laboratory, not independently replicated\",\n        \"Whether EROS directly chaperones RAC1 or affects it indirectly through NOX2 is unresolved\",\n        \"In vivo vascular phenotype of EROS deficiency not tested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of EROS interaction with P2X7/P2X1 clients, the full client repertoire of EROS as an ER chaperone, the mechanism governing EROS recycling or degradation after client release, and the in vivo relevance of EROS in non-immune cell types such as endothelium.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No structural data for EROS–P2X7 or EROS–P2X1 complexes\",\n        \"Comprehensive client profiling via unbiased interactomics not yet performed across tissue types\",\n        \"Post-dissociation fate of EROS protein is unknown\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [2, 3, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [2, 3, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2, 3]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 3, 4]}\n    ],\n    \"complexes\": [\n      \"NADPH oxidase (NOX2–p22phox–EROS)\"\n    ],\n    \"partners\": [\n      \"CYBB\",\n      \"CYBA\",\n      \"P2RX7\",\n      \"P2RX1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}